Skip to main content
SpringerLink
Log in

Medical management of atrial fibrillation

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Atrial fibrillation (AF) is the most common sustained tachyarrhythmia encountered in clinical practice. The management of AF remains associated with many challenges that make its treatment a vexing problem. However, in recent years extraordinary progress has been made in the understanding and management of AF. In general, antiarrhythmic drugs for rhythm control have been disappointing. We have a better understanding of pharmacologic cardioversion and this has led to newer strategies, such as intermittent therapy. Several studies have been completed comparing pharmacologic rhythm control with pharmacologic heart rate control. There is also an emerging body of evidence concerning the value of adjunctive drug use for rhythm control using drugs that would not usually be considered to be antiarrhythmic. Finally, antithrombotic therapy is an increasingly important part of the medical management of AF. This article summarizes the results of many of the recent publications and their clinical implications concerning management of this common rhythm disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Boriani G, Diemberger I, Bif. M, et al.: Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 2004, 64:2741–2762. A comprehensive review of the principles of and drugs used for pharmacologic cardioversion.

    Article  PubMed  CAS  Google Scholar 

  2. Roy D, Rowe BH, Stiell IG, et al.: A randomized, controlled trial of RSD 1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004, 44:2355–2361.

    Article  PubMed  CAS  Google Scholar 

  3. Miller MR, McNamara RL, Segal JB, et al.: Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm. J Fam Prac 2000, 49:1033–1046. A review of the Efficacy of currently available antiarrhythmic drugs used for the maintenance of sinus rhythm.

    CAS  Google Scholar 

  4. Singh BN, Singh SN, Reda DJ, et al.: Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) investigators. N Engl J Med 2005, 352:1861–1872.

    Article  PubMed  CAS  Google Scholar 

  5. Fuster V, Ryden LE, Asinger RW, et al.: ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation. A report of the American Heart Association Task Force on Practice Guidelines and Policy Conferences (Committee of Develop Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with North American society of Pacing and Electrophysiology. Eur Heart J 2001, 22:1852–1923. This is the currently published version of the American College of Cardiology/American Heart Association/European Society of Cardiology guidelines for treatment of AF. The guidelines have been recently revised.

    Article  PubMed  CAS  Google Scholar 

  6. Pritchett EL, Page RL, Connolly SJ, et al.: Antiarrhythmic effects of azimilide in atrial fibrillation: Efficacy and dose-response. J Am Coll Cardiol 2000, 35:794–802.

    Article  Google Scholar 

  7. Touboul P, Brugada J, Capucci A, et al.: Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J 2003, 24:1481–1487.

    Article  PubMed  CAS  Google Scholar 

  8. Olshansky B, Rosenfeld LE, Warner AL, et al.:The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 2004, 43:1201–1208.

    Article  PubMed  Google Scholar 

  9. Wyse DG: Rate control vs rhythm control strategies in atrial fibrillation. Prog Cardiovasc Dis 2005, 48:125–138. A comprehensive review of the rate control and rhythm control strategies and a summary of the trial results comparing these two strategies.

    Article  PubMed  Google Scholar 

  10. Wyse DG, Simpson CS: Rate control versus rhythm control -- decision making. Can J Cardiol 2005, 21(Suppl B):15B-8B. A summary of factors that favor the selection of rhythm control versus rate control in an individual patient.

    PubMed  Google Scholar 

  11. Hersi A, Wyse DG: Management of atrial fibrillation. Curr Probl Cardiol 2005, 30:175–233. A more detailed discussion of many of the aspects of AF management that are presented in the present review, along with many more references.

    Article  PubMed  CAS  Google Scholar 

  12. Nieuwlaat R, Capucci A, Camm AJ, et al.: Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Euro Heart J 2005, 26:2422–2434.

    Article  Google Scholar 

  13. Gage BF, Van Walraven C, Pearce L, et al.: Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004, 110:2287–2292.

    Article  PubMed  CAS  Google Scholar 

  14. Gage BF, Waterman AD, Shannon W, et al.: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864 -2870.

    Article  PubMed  CAS  Google Scholar 

  15. Atrial Fibrillation Investigators: Risk factor for stroke and Efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.

  16. DiMarco JP, Flaker G, Waldo AL, et al.: Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005, 149:650–656.

    Article  PubMed  Google Scholar 

  17. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362:1691–1698.

    Article  PubMed  CAS  Google Scholar 

  18. Albers GW, Diener HC, Frison L, et al.: Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005, 293:690–698.

    Article  PubMed  Google Scholar 

  19. Lozano H, Conde C, Florin T, et al.: Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. Heart Rhythm 2005, 2:1000–1007.

    Article  PubMed  Google Scholar 

  20. Ehrlich JR, Hohnloser SH, Nattel S: Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006, 27:512–518. A nice review of the current status of nonantiarrhythmic therapies that may help to prevent development of AF or assist in maintaining sinus rhythm.

    Article  PubMed  CAS  Google Scholar 

  21. McMurray J, Køber L, Robertson M, et al.: Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005, 45:525–530.

    Article  PubMed  CAS  Google Scholar 

  22. Wachtell K, Lehto M, Gerdts E, et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End point reduction in hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:712–719.

    Article  PubMed  CAS  Google Scholar 

  23. Alboni P, Botto GL, Baldi N, et al.: Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004, 351:2384–2391.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Libin Cardiovascular Institute of Alberta, University of Calgary, Room G009, 3330 Hospital Drive NW, T2N 4N1, Calgary, AB, Canada

    D. George Wyse MD, PhD

Authors
  1. Ahmad Hersi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. George Wyse MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. George Wyse MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hersi, A., Wyse, D.G. Medical management of atrial fibrillation. Curr Cardiol Rep 8, 323–329 (2006). https://doi.org/10.1007/s11886-006-0070-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-006-0070-6

Keywords

Search

Navigation